Cerebellar Large B-cell Lymphoma: A Case Report Cerebellar Large B-cell Lymphoma: A Case Report
This case report reviews the diagnosis, pathophysiology and management of primary central nervous system lymphoma, an aggressive non-Hodgkin lymphoma.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 9, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Allergan Halts Sales in Europe of Textured Breast Implants Linked to Rare Cancer
The company ’ s product, in use worldwide, has been under scrutiny since women began developing a type of lymphoma. (Source: NYT Health)
Source: NYT Health - December 19, 2018 Category: Consumer Health News Authors: DENISE GRADY Tags: Implants Breasts Medical Devices Plastic Surgery Non-Hodgkin's Lymphoma France Allergan Inc Cancer Recalls and Bans of Products Europe Source Type: news

Impact of Checkpoint Blockade Therapy on Subsequent Treatment in Non-Hodgkin Lymphoma Patients
Research presented at ASH 2018 examined whether checkpoint blockade therapy sensitizes patients with relapsed/refractory NHL to consequent treatment. (Source: CancerNetwork)
Source: CancerNetwork - December 6, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

Medical News Today: Does HIV increase cancer risk?
HIV can weaken a person ’s immune system, which can increase the risk of certain types of cancer. Such cancers include Kaposi’s sarcoma, non-Hodgkin lymphoma, and cervical, lung, anal, and oral cancer. However, effective treatment can significantly reduce the risk of developing these cancers. Learn more here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 4, 2018 Category: Consumer Health News Tags: HIV and AIDS Source Type: news

ASH: High Response to Tx After Checkpoint Blockade in NHL, HL
MONDAY, Dec. 3, 2018 -- For heavily pretreated patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL), response rates are high for treatment subsequent to checkpoint blockade therapy (CBT), according to two... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 3, 2018 Category: Pharmaceuticals Source Type: news

Genetically engineered immune cells show promise for fighting relapsed blood cancer
(UNC Lineberger Comprehensive Cancer Center) At the 60th Annual American Society of Hematology Annual Meeting in San Diego on Monday, UNC Lineberger Comprehensive Cancer Center researchers presented preliminary results from a clinical study of an investigational cellular immunotherapy for Hodgkin lymphoma and non-Hodgkin lymphoma expressing the CD30 protein marker. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 3, 2018 Category: Cancer & Oncology Source Type: news

Global trial shows CAR T therapy can lead to durable remissions in non-Hodgkin's lymphoma
(University of Pennsylvania School of Medicine) In an update to a global clinical trial stretching from Philadelphia to four continents, the chimeric antigen receptor (CAR) T cell therapy Kymriah ® (tisagenlecleucel, formerly CTL019) led to long-lasting remissions in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 1, 2018 Category: International Medicine & Public Health Source Type: news

Non-Hodgkin Lymphoma | Medscape Non-Hodgkin Lymphoma | Medscape
Non-Hodgkin lymphoma is the fifth most common cancer in the United States, accounting for about 4% of all malignancies in both men and women. The disease comprises a variety of cancers of the lymphatic system exclusive of Hodgkin lymphoma. (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 30, 2018 Category: Consumer Health News Tags: Resource Center Source Type: news

Truxima Approved as First Biosimilar to Non-Hodgkin's Lymphoma Drug
Title: Truxima Approved as First Biosimilar to Non-Hodgkin's Lymphoma DrugCategory: Health NewsCreated: 11/28/2018 12:00:00 AMLast Editorial Review: 11/29/2018 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - November 29, 2018 Category: Cancer & Oncology Source Type: news

FDA approves first biosimilar to Roche cancer drug Rituxan
Celltrion Inc's Truxima on Wednesday became the first biosimilar to Roche Holding AG's $7-billion-per-year cancer drug Rituxan to be approved in the United States to treat non-Hodgkin's lymphoma. (Source: Reuters: Health)
Source: Reuters: Health - November 29, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

First Biosimilar Rituximab for Lymphoma Approved in US First Biosimilar Rituximab for Lymphoma Approved in US
Truxima, designed for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin lymphoma, can be used as a single agent or in combination with chemotherapy.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 28, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA approves first biosimilar to Roche's cancer drug Rituxan
Celltrion Inc's Truxima on Wednesday became the first biosimilar to Roche Holding AG's $7-billion-per-year cancer drug Rituxan to be approved in the United States to treat non-Hodgkin's lymphoma. (Source: Reuters: Health)
Source: Reuters: Health - November 28, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

U.S. FDA approves first biosimilar to Roche's cancer drug Rituxan
The U.S. Food and Drug Administration on Wednesday approved Celltrion Inc's Truxima, making it the first biosimilar to Roche Holding AG's Rituxan available in the United States to treat non-Hodgkin's lymphoma. (Source: Reuters: Health)
Source: Reuters: Health - November 28, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves First Biosimilar to Non-Hodgkin's Lymphoma Drug
WEDNESDAY, Nov. 28, 2018 -- Truxima (rituximab-abbs) has been approved by the U.S. Food and Drug Administration as the first biosimilar to the non-Hodgkin's lymphoma drug Rituxan, the agency said today. Truxima, as with Rituxan, is approved to treat... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 28, 2018 Category: Pharmaceuticals Source Type: news

Truxima Approved as First Biosimilar to Non-Hodgkin's Lymphoma Drug
WEDNESDAY, Nov. 28, 2018 -- Truxima (rituximab-abbs) has been approved by the U.S. Food and Drug Administration as the first biosimilar to the non-Hodgkin's lymphoma drug Rituxan, the agency said Wednesday. A biosimilar is a biological product that... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 28, 2018 Category: General Medicine Source Type: news

I Won a Historic Lawsuit, But May Not Live to Get the Money
Dewayne Anthony Lee Johnson has always just gone by Lee. He lived a modest life for 42 years, and was devastated when he was diagnosed with terminal cancer in 2014. Now 46, as he struggles with his advancing illness, Johnson has found sudden celebrity with a historic victory over one of the world’s most powerful and controversial corporations – Monsanto Co. Johnson sued Monsanto alleging that he developed a deadly form of non-Hodgkin lymphoma after being drenched with the company’s herbicides, which he sprayed as part of his job as school groundskeeper. In Aug. 2018, a jury in San Francisco unanimously f...
Source: TIME: Health - November 21, 2018 Category: Consumer Health News Authors: Carey Gillam Tags: Uncategorized Cancer monsanto Source Type: news

Macrophage Checkpoint Blockade: New Immunotherapy Strategy Macrophage Checkpoint Blockade: New Immunotherapy Strategy
A new immunotherapy strategy targets the macrophage and innate immunity. The remarkable response seen in non-Hodgkin's lymphoma paves the way for this approach in other malignancies.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 31, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

UCLA cancer treatment gave this woman more than just hope
Denise Delatorre, 59, has always been a problem solver. As a real estate agent and single parent to her now 24-year-old son, she had to be.“If you’re working off straight commissions and you’re a single parent, it can be very taxing,” Delatorre said. “I’ve become an expert fixer, and I’m really good at helping other people. I enjoy doing that.”But in 2015, when she started having hot flashes, night sweats and feeling bloated, Delatorre knew she needed to focus on herself. She made an appointment with a doctor, hoping he would say that her symptoms were caused by menopause.But...
Source: UCLA Newsroom: Health Sciences - October 31, 2018 Category: Universities & Medical Training Source Type: news

The Invisible, Hungry Hand
A worker on a farm in Kiambu district, central Kenya, that produces tea for export. Nearly 80 percent of rural farmers in developing countries earn less than USD1.25 per day. Credit: Charles Wachira/IPSBy Tharanga YakupitiyageUNITED NATIONS, Oct 24 2018 (IPS)The very people who help put food on our tables often face numerous human rights violations, forcing them go to bed hungry.In an annual report set to be presented to governments at the United Nations this week, Special Rapporteur on the Right to Food Hilal Elver found that agricultural workers worldwide continue to face barriers in their right to food including dangero...
Source: IPS Inter Press Service - Health - October 24, 2018 Category: International Medicine & Public Health Authors: Tharanga Yakupitiyage Tags: Development & Aid Economy & Trade Featured Food & Agriculture Global Global Governance Headlines Health IPS UN: Inside the Glasshouse Labour Poverty & SDGs Regional Categories TerraViva United Nations Food and Agriculture Organiz Source Type: news

You Can Cut Your Cancer Risk By Eating Organic, New Study Says
(CNN) — You can protect yourself from cancer by eating organic, a new study suggests. Those who frequently eat organic foods lowered their overall risk of developing cancer, a study published Monday in JAMA Internal Medicine finds. Specifically, those who primarily eat organic foods were more likely to ward off non-Hodgkin lymphoma and postmenopausal breast cancer compared to those who rarely or never ate organic foods. Led by Julia Baudry, an epidemiologist at Institut National de la Sante et de la Recherche Medicale in France, a team of researchers looked at the diets of 68,946 French adults. More than three-quarte...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - October 22, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Cancer Local TV Organic Source Type: news

Love Organics? Your Odds for Some Cancers May Fall
Eating more organically grown foods was linked to a 34 percent reduced risk of postmenopausal breast cancer, a 76 percent decreased risk for all lymphomas and an 86 percent reduced risk for non-Hodgkin lymphoma, a recent study found. (Source: WebMD Health)
Source: WebMD Health - October 22, 2018 Category: Consumer Health News Source Type: news

You can cut your cancer risk by eating organic, a new study says
You can protect yourself from cancer by eating organic, a new study suggests. Those who frequently eat organic foods lowered their overall risk of developing cancer, a study published Monday in JAMA Internal Medicine finds. Specifically, those who primarily eat organic foods were more likely to ward off non-Hodgkin lymphoma and postmenopausal breast cancer compared to those who rarely or never ate organic foods. (Source: CNN.com - Health)
Source: CNN.com - Health - October 22, 2018 Category: Consumer Health News Source Type: news

Paul Allen ’s death shines light on non-Hodgkin lymphoma
The co-founder of Microsoft died Monday from complications with the disease, which is one of the most common cancers in the United States (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - October 16, 2018 Category: Consumer Health News Source Type: news

Non-Hodgkin lymphoma: Key questions answered
Lymphatic system cancer has become far more prevalent in recent years (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - October 16, 2018 Category: Consumer Health News Source Type: news

Microsoft co-founder Paul Allen dead at 65
Paul Allen, a pioneer of personal computing, died Monday. Allen co-founded Microsoft with Bill Gates, and later bought the Seattle Seahawks. Allen had been fighting non-Hodgkin's lymphoma. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - October 16, 2018 Category: Consumer Health News Source Type: news

Updated GADOLIN Study Shows Survival Benefit in Indolent NHL Updated GADOLIN Study Shows Survival Benefit in Indolent NHL
An updated analysis of the GADOLIN study confirms the PFS benefit of obinutuzumab and bendamustine in rituximab-refractory indolent non-Hodgkin lymphoma.Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 12, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

'The world is against them': new era of cancer lawsuits threaten Monsanto
A landmark verdict found Roundup caused a man ’s cancer, paving the way for thousands of other families to seek justiceDean Brooks grasped on to the shopping cart, suddenly unable to stand or breathe.Later, at a California emergency room, a nurse with teary eyes delivered the news, telling his wife, Deborah, to hold out hope for a miracle. It was December 2015 when they learned that a blood cancer called non-Hodgkin lymphoma (NHL) was rapidly attacking the man ’s body and immune system.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - October 8, 2018 Category: Science Authors: Sam Levin and Carey Gillam Tags: Agriculture US news California Cancer Source Type: news

Cancer survivor has welcomed his 'miracle' baby
Simon Thompson, 32, from Kent, was rushed to hospital when a 'dental abscess' failed to improve despite antibiotics. He was later diagnosed with advanced Non Hodgkin's lymphoma. (Source: the Mail online | Health)
Source: the Mail online | Health - September 20, 2018 Category: Consumer Health News Source Type: news

Hepatitis B Virus and Risk of Non-Hodgkin Lymphoma Hepatitis B Virus and Risk of Non-Hodgkin Lymphoma
Several prior studies have suggested that chronic HBV infection can increase the risk of non-Hodgkin's lymphoma. What's the current best evidence on this possible relationship?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 11, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Cases Transferred To Roundup MDL Bring Total Glyphosate Actions To More Than 500
SAN FRANCISCO - The Judicial Panel on Multidistrict Litigation (JPMDL) on Aug. 27 issued a conditional transfer order sending another 27 cases to the Roundup multidistrict litigation in the U.S. District Court for the Northern District of California, bring the total number of cases in the MDL in which the plaintiffs allege that their exposure to the Roundup herbicide caused them to develop non-Hodgkin lymphoma (NHL) to more than 500 (In Re: Roundup Products Liability Litigation, No. 2741, JPMDL). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - September 6, 2018 Category: Medical Law Source Type: news

Cancer: Costly non-Hodgkin lymphoma drug rejected for NHS use
NICE has rejected a new blood cancer drug, Yescarta, which is for the treatment of non-Hodgkin lymphoma, for NHS use due to the drug being too expensive. (Source: Daily Express - Health)
Source: Daily Express - Health - August 29, 2018 Category: Consumer Health News Source Type: news

NICE consults on expensive blood cancer treatment
NICE has invited comments and further evidence on a new treatment for aggressive subtypes of non-Hodgkin lymphoma called diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma that could lead to it being made available for use on the NHS. (Source: NHS Networks)
Source: NHS Networks - August 29, 2018 Category: UK Health Source Type: news

NICE rejects Gilead CAR-T cancer cell therapy
The company's CAR-T drug Yescarta, which had just received approval from the European Commission for two aggressive forms of non-Hodgkin lymphoma, was found to be too expensive according to Britain ’s state-funded health service. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - August 28, 2018 Category: Pharmaceuticals Source Type: news

Makers of a revolutionary cancer treatment asked to slash its 'eye-watering' cost
Nice today announced it was unable to approve a type of CAR-T therapy, called Yescarta, for thousands of non-Hodgkin lymphoma patients on the health service because it is so expensive. (Source: the Mail online | Health)
Source: the Mail online | Health - August 28, 2018 Category: Consumer Health News Source Type: news

Cancer patient who was awarded $289M in Monsanto case speaks out
Dewayne "Lee" Johnson alleges that his use of Monsanto's weed killer Roundup contributed to his non-Hodgkin's lymphoma (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - August 18, 2018 Category: Consumer Health News Source Type: news

Chemical giant ordered to pay $289M in Roundup cancer trial
"The simple fact is he is going to die," said the attorney who represented Dewayne Johnson, who has non-Hodgkin's lymphoma (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - August 11, 2018 Category: Consumer Health News Source Type: news

New Treatment for Non-Hodgkin Lymphoma Approved
Title: New Treatment for Non-Hodgkin Lymphoma ApprovedCategory: Health NewsCreated: 8/8/2018 12:00:00 AMLast Editorial Review: 8/9/2018 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 9, 2018 Category: Cancer & Oncology Source Type: news

FDA Approves Poteligeo for Rare Types of Non-Hodgkin Lymphoma
WEDNESDAY, Aug. 8, 2018 -- Poteligeo (mogamulizumab) injection has been approved by the U.S. Food and Drug Administration to treat adults with two rare types of non-Hodgkin lymphoma. The drug was approved to treat relapsed or refractory mycosis... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 8, 2018 Category: Pharmaceuticals Source Type: news

New Treatment for Non-Hodgkin Lymphoma Approved
WEDNESDAY, Aug. 8, 2018 -- Poteligeo (mogamulizumab) injection has been approved by the U.S. Food and Drug Administration to treat adults with two types of non-Hodgkin lymphoma. The drug was approved to treat relapsed or refractory mycosis... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 8, 2018 Category: General Medicine Source Type: news

FDA approves treatment for two rare types of non-Hodgkin lymphoma
FDA approves new drug for the treatment of adults with relapsed or refractory mycosis fungoides or S ézary syndrome after at least one prior systemic therapy (Source: Food and Drug Administration)
Source: Food and Drug Administration - August 8, 2018 Category: American Health Source Type: news

FDA approves treatment for two rare types of non-Hodgkin lymphoma
The U.S. Food and Drug Administration today approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. This approval provides a new treatment option for patients with MF and is the first FDA approval of a drug specifically for SS. (Source: World Pharma News)
Source: World Pharma News - August 8, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Carcinogenicity Of Glyphosate Debated At Opening Of Trial Against Monsanto
SAN FRANCISCO - The attorney for a man who claims that Monsanto Co. is responsible for his cancer on July 9 opened a bellwether trial in California state court by contending that the company has known since 1998 that its herbicide Roundup, which contains the active ingredient glyphosate, is connected to non-Hodgkin lymphoma (NHL), yet it failed to warn consumers (DeWayne Johnson v. Monsanto Company, No. CGC 16550128, Calif. Super., San Francisco Co.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - July 20, 2018 Category: Medical Law Source Type: news

Judge: Glyphosate Plaintiffs' Experts Are Admissible In Case Against Monsanto
SAN FRANCISCO - A federal judge in California on July 10 ruled that the experts for plaintiffs who have sued Monsanto Co. in multidistrict litigation related to the herbicide Roundup should be admitted because the plaintiffs have presented evidence from which a reasonable jury could conclude that glyphosate, the active ingredient in Roundup, can cause non-Hodgkin lymphoma (NHL) at "human-relevant doses" (In re: Roundup Products Liability Litigation, MDL No. 2741, N.D. Calif.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - July 20, 2018 Category: Medical Law Source Type: news

Children's Hospital maker space to use STEAM-inspired problem-solving
UPMC Children's Hospital of Pittsburgh will unveil Matt's Maker Space, where patients will be able to engage in STEAM-related problem-solving to both learn and distract them from their illnesses. The space is named to honor 12-year-old Matt Conover who died of non-Hodgkin's lymphoma, and the hospital will host an event at 1 p.m. Tuesday to celebrate its opening with community partners Children's Museum of Pittsburgh, Sen. John Heinz History Center, the Andy Warhol Museum, Mt. Lebanon Schoo l District… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 16, 2018 Category: Biotechnology Authors: Stacey Federoff Source Type: news

EPA official whitewashed glyphosate links to non-Hodgkin lymphoma in order to protect Monsanto profits
(Natural News) The EPA has been caught red-handed whitewashing studies of Monsanto’s cash cow, glyphosate. The federal agency purposely ignored data showing a clear connection between glyphosate and non-Hodgkin’s lymphoma. In addition to ignoring the obvious threat of glyphosate, agency regulators obscured the opinions of the Scientific Advisory Panel, charged with reviewing the EPA’s glyphosate... (Source: NaturalNews.com)
Source: NaturalNews.com - July 3, 2018 Category: Consumer Health News Source Type: news

Nordic Nanovector Appoints Eduardo Bravo as Chief Executive Officer
OSLO, 25 June, 2018 -- (Healthcare Sales & Marketing Network) -- Nordic Nanovector ASA (OSE: NANO) announces that Eduardo Bravo has been appointed as its Chief Executive Officer. Mr. Bravo brings more than 25 years' experience in the biopharmaceutical ... Biopharmaceuticals, Oncology, Personnel Nordic Nanovector, Betalutin, non-Hodgkin's lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 25, 2018 Category: Pharmaceuticals Source Type: news

VHIO is the first Spanish site to conduct CAR T cell trial against lymphoma in Europe
(Vall d'Hebron Institute of Oncology) Launched: First international clinical trial with CAR T cell therapy for patients with aggressive B-cell non-Hodgkin lymphoma (B-Cell NHL) in Europe.The trial has been designed to determine the efficacy and safety of JCAR017, a chimeric antigen receptor (CAR) T cell therapy, in the treatment of clinically selected adult patients with relapsed or refractory disease (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 15, 2018 Category: International Medicine & Public Health Source Type: news

Results of Novel Mesothelioma Drug Presented at ASCO Meeting
A multicenter phase II clinical trial involving the latest orally administered protein inhibitor drug has shown considerable promise in helping control malignant mesothelioma. The effectiveness of tazemetostat was presented last week at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. The trial study, which will conclude late 2018, involves 74 previously treated patients with recurring mesothelioma. “We’ve seen benefit for some patients with this treatment and patients who have benefited over a long period of time,” medical oncologist Dr. Marianna Koczywas, City of Hope Cancer T...
Source: Asbestos and Mesothelioma News - June 14, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Antiviral Treatments Reduce Cancer Risk for HIV Patients
MONDAY, June 11, 2018 -- Long-term antiviral treatment cuts the risk of cancer in HIV patients as they age, a new study says. People with HIV are at increased risk for both AIDS-related cancers (Kaposi sarcoma, non-Hodgkin lymphoma or invasive... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 11, 2018 Category: General Medicine Source Type: news

Monsanto Denies Liability, Says Roundup Is Non-Toxic, Non-Carcinogenic
SAN FRANCISCO - Monsanto Co. on May 29 filed another answer to one of the more than 400 lawsuits in the multidistrict litigation for Roundup, denying any liability for injuries - including non-Hodgkin lymphoma - that plaintiffs say were caused by exposure to the herbicide's active ingredient glyphosate (In re: Roundup Products Liability Litigation, MDL No. 2741, N.D. Calif.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - June 5, 2018 Category: Medical Law Source Type: news